Technical Analysis for ADAP - Adaptimmune Therapeutics plc

Grade Last Price % Change Price Change
grade C 5.16 -3.73% -0.20
ADAP closed down 3.73 percent on Friday, December 14, 2018, on 57 percent of normal volume.

Trend Table & Recent Signals
ADX Long-Term Intermediate-Term Short-Term
Weak or Absent Down Down Down
See historical ADAP trend table...

Date Alert Name Type % Chg
Dec 14 180 Bearish Setup Bearish Swing Setup 0.00%
Dec 14 Outside Day Range Expansion 0.00%
Dec 13 Narrow Range Bar Range Contraction -3.73%
Dec 13 NR7 Range Contraction -3.73%
Dec 13 Inside Day Range Contraction -3.73%
Dec 12 Fell Below 20 DMA Bearish -1.71%
Dec 12 New 52 Week Low Weakness -1.71%
Dec 12 Lower Bollinger Band Touch Weakness -1.71%
Dec 11 20 DMA Support Bullish -10.26%
Dec 11 Outside Day Range Expansion -10.26%

Older signals for ADAP ...

Get a Trading Sidekick!

Let us help you stay on top of your investments. We will alert you to important technical developments on your portfolio & watchlist.
Configure default chart indicators
Basic chart:
Profile
Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, focuses on the provision of cancer immunotherapy products based on its T-cell receptor platform. Its platform enables to identify cancer targets in the form of peptides, which are short sequences of amino acids; find and genetically engineer T-cell receptors (TCR); and produce TCR therapeutic candidates for administration to patients. The company's lead product candidate includes NY-ESO, a cancer antigen, which is in Phase I/II clinical trials for the treatment of patients with solid tumors and hematological malignancies, including synovial sarcoma, multiple myeloma, melanoma, ovarian cancer, and esophageal cancer, as well as for non-small cell lung cancer. It is also developing MAGE A-10 TCR that is in preclinical stage for the treatment of breast and lung cancer, and other solid tumors, as well as a TCR therapeutic candidate directed to Alpha Fetoprotein. The company was founded in 2014 and is headquartered in Abingdon, the United Kingdom.
Is ADAP a Buy, Sell or Hold?
Indicator Bull Case Neutral / Hold Bear Case
50 DMA
200 DMA
ADX Trend
Oversold / Overbought
Relative Strength
Summary: Counts: 0 bullish, 2 bearish and 3 neutral indicators. You may wish to incorporate that into your trading strategies.
Indicators
Indicator Value
52 Week High 14.625
52 Week Low 4.82
Average Volume 654,824
200-Day Moving Average 10.3834
50-Day Moving Average 7.5643
20-Day Moving Average 5.596
10-Day Moving Average 5.723
Average True Range 0.5272
ADX 24.31
+DI 17.0592
-DI 29.7428
Chandelier Exit (Long, 3 ATRs ) 4.9884
Chandelier Exit (Short, 3 ATRs ) 6.4016
Upper Bollinger Band 6.2475
Lower Bollinger Band 4.9445
Percent B (%b) 0.17
BandWidth 23.284489
MACD Line -0.4804
MACD Signal Line -0.5711
MACD Histogram 0.0907
Fundamentals Value
Market Cap 482.56 Million
Num Shares 93.5 Million
EPS -0.99
Price-to-Earnings (P/E) Ratio -5.21
Price-to-Sales 39.39
Price-to-Book 2.97
PEG Ratio 0.17
Dividend 0.00
Dividend Yield 0.00%
Pivot Point Level Traditional / Classic Fibonacci Demark Woodie Camarilla
Resistance 4 (R4) 5.58
Resistance 3 (R3) 5.61 5.49 5.51
Resistance 2 (R2) 5.49 5.39 5.48 5.49
Resistance 1 (R1) 5.33 5.32 5.27 5.30 5.46
Pivot Point 5.21 5.21 5.19 5.20 5.21
Support 1 (S1) 5.05 5.11 4.99 5.02 4.86
Support 2 (S2) 4.93 5.04 4.92 4.83
Support 3 (S3) 4.77 4.93 4.81
Support 4 (S4) 4.74